Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
about
Randomized, multicentre assessment of the efficacy and safety of ASAQ--a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malariaGametocyte clearance dynamics following oral artesunate treatment of uncomplicated falciparum malaria in Malian childrenSelection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina FasoIdentification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparumFive years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll outSurveillance of travellers: an additional tool for tracking antimalarial drug resistance in endemic countriesDelayed anemia assessment in patients treated with oral artemisinin derivatives for uncomplicated malaria: a pooled analysis of clinical trials data from Mali.Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa.Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali.In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations.Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoProtective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved ToolPatterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data.Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.Efficacy of sulphadoxine-pyrimethamine + artesunate, sulphadoxine-pyrimethamine + amodiaquine, and sulphadoxine-pyrimethamine alone in uncomplicated falciparum malaria in MaliComparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.Drug resistance maps to guide intermittent preventive treatment of malaria in African infants.Hematologic parameters in pediatric uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa.Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.Assessing anti-malarial drug effects ex vivo using the haemozoin detection assay.Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in MaliA thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon.Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, MaliIdentification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania.Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the futureNo evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali.Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impactSeasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in MaliEfficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger.Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa.Haemoglobin changes and risk of anaemia following treatment for uncomplicated falciparum malaria in sub-Saharan Africa.In Vivo Efficacy and Parasite Clearance of Artesunate + Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine in Mali.Artemisinin-based combinations versus amodiaquine plus sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Faladje, MaliSulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquito survival.Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in MaliSelection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysisAmodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes.Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda.
P2860
Q21034136-E86AE461-6E67-46D7-8E43-6D21172B0B9DQ22773191-E0186711-5622-4B07-BD6D-0F82409A6126Q28125901-39DE0F2B-781F-4E3A-8447-891F274F8692Q28473923-CA2540A3-5347-4071-9E01-A63FCC07D905Q28477515-0CBBE25B-F9D8-4DC1-90D0-5D3F7822E082Q28534753-B46436BA-19D2-4CE8-B69D-AFAFEC61AA39Q30850979-1BA1DA2D-C3C8-4002-92E7-F781211EB6A7Q33399342-AF5E88CD-3680-4D82-BE3B-BD7BFAE0BC56Q33645358-4956D079-50C7-46FE-BADD-426FDED966BEQ33676088-100301BC-C58B-478B-84D7-226FE5AEA73CQ33723453-4DE40505-BCED-47C5-9A3F-AF69326C02D6Q33826359-B760EE44-D9B0-466C-8FC9-E978A9482065Q33875677-1547C686-6696-45D9-960F-1A8A0213D931Q33893267-F10FFF39-8B8A-47DE-89E2-8586CCD117DCQ34281680-AAEFC370-32C3-4ABD-BD11-CB1A2979806DQ35078892-6F818248-E580-4148-A77E-C1323F4579D1Q35137471-DE8E0E36-65F3-4ED8-9747-583229C77AC4Q35228689-91182B18-0B71-488E-A9DD-DAF506FD94CDQ35245962-824ECB90-6CB5-4F77-BA19-C09DCC85F33CQ35356543-2888D893-96E8-4DED-9F2E-3CAA0A5B11E7Q35368698-CB339FAB-E921-41D3-8A11-B1604E784CA1Q35398338-A50724D3-D2CF-47DB-982C-EB37371864AFQ35549781-276A5FCC-F543-4D21-A2E8-592C20349C8FQ35616221-0DBDB243-DD50-4CAB-8D04-3F475667C6BDQ35830639-31D99E7F-353F-4B57-B5C6-F01AEECCB59FQ36012531-81BD7FB9-06CB-4ADF-A5CD-B920EA059CA9Q36080109-A97D8330-5C42-4819-8955-35CA9B3C6F97Q36080127-112DED5B-D9DB-4B5A-8721-B09FDA60473CQ36143003-571CCAF6-5B49-48CF-BA97-2AFBE8B2D182Q36173444-AF27FF10-17E3-4B52-979D-EAAAAB79AB0DQ36309115-C47FB518-5025-4CF8-92B0-02C1EEC012A1Q36413462-249A7FCB-EDD4-41BA-BCE6-39E56063A47BQ36644511-54804038-3E87-400A-89D5-ACC61D3239EEQ37074386-FBB3C536-87FB-4F6F-BD9E-90F3BB728406Q37097339-5881A20A-EBDC-4D21-8A05-13599A9231FCQ37117352-471A8268-5605-4790-B133-8E45CD06C54CQ37233322-705D296A-1574-4D02-8EE7-5F3B88BF699CQ37350167-8F3B33AF-2217-4256-B79E-7626B4781E4CQ37423034-B673A68E-2DFF-4139-9101-3722E07DD2DCQ37436582-D9A1FFF6-772B-4183-922F-0AF3CAE3D628
P2860
Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Efficacy, safety, and selectio ...... esistance by two ACTs in Mali.
@en
type
label
Efficacy, safety, and selectio ...... esistance by two ACTs in Mali.
@en
prefLabel
Efficacy, safety, and selectio ...... esistance by two ACTs in Mali.
@en
P50
P1476
Efficacy, safety, and selectio ...... esistance by two ACTs in Mali.
@en
P2093
Bakary Sidibe
Sekou Toure
P304
P407
P50
P577
2008-03-01T00:00:00Z